Artiria Medical is a Swiss-based MedTech startup that specializes in the development of innovative solutions for minimally invasive stroke treatments. The company operates in the neurovascular medical devices market, serving neurointerventional surgeons and their patients.

Artiria's primary offering is a real-time deflectable guidewire, a game-changing technology that enhances the control and navigation of catheters and guidewires during neurointerventional procedures. This technology, which has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), allows for seamless access to neurovascular targets, even in complex vascular anatomies. Essentially, it makes it easier and safer for surgeons to reach and treat areas of the brain affected by stroke.

The company's business model revolves around the design, development, and sale of these endovascular treatment devices. They generate revenue through the sales of their FDA-approved guidewires to hospitals and clinics.

Artiria has demonstrated significant financial potential, having raised CHF 3.8 million in funding, including a CHF 2.7 million grant from the EIC accelerator program and CHF 1.1 million in bridge financing. Additionally, the company has received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI).

Artiria also holds the ISO 13485 certification from TÜV SÜD for its Quality Management System, further solidifying its commitment to high-quality, reliable medical devices.

Keywords: MedTech, Stroke Treatment, Neurovascular, Minimally Invasive, Guidewire, FDA 510(k) Clearance, ISO 13485 Certification, Endovascular Devices, Neurointerventional Surgery, Swiss Startup.